Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 0.38 |
| ▸ | SGK1 | O00141 | 13/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31107020 | 0.85 | SGK1 (0.38) | AKT2SGK1PLK4PAK4PDE2A | |
| SCHEMBL24955620 | 0.85 | SGK1 (0.38) | AKT2SGK1PLK4PAK4PDE2A | |
| SCHEMBL55757 | 0.82 | MTOR (0.40) | AKT2SGK1PLK4PAK4PDE2A | |
| SCHEMBL3984786 | 0.74 | PIK3CA (0.49) | AKT2SGK1BTK | |
| SCHEMBL22282186 | 0.74 | NT5E (0.39) | AKT2SGK1PLK4PAK4PDE2A | |
| SCHEMBL31106994 | 0.71 | SGK1 (0.38) | SGK1PLK4PAK4PDE2A | |
| SCHEMBL29705692 | 0.67 | HPGDS (0.61) | SGK1PLK4PAK4PDE2A | |
| SCHEMBL22282069 | 0.67 | HPGDS (0.61) | SGK1PLK4PAK4PDE2A | |
| SCHEMBL53863 | 0.66 | PLK4 (0.47) | PLK4PAK4PDE2ABTK | |
| SCHEMBL3754341 | 0.66 | HPGDS (0.53) | SGK1PLK4PAK4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4353732-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | ENTPD5, ENTPD1, ENTPD2 | AKT2 3099/4885SGK1 3558/4885PLK4 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.